HLB LIFE SCIENCE CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16,950 KRW | -3.03% |
|
+1.19% | +48.03% |
| Mar. 22 | HLB Life Science to Raise 148.5 Billion Won via Shares Issuance; Shares Decline 8% | MT |
| Mar. 21 | HLB Life Science Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2022 | 99.59B 72.4M | Sales 2023 | 97.99B 71.24M | Capitalization | 1,166B 847M |
|---|---|---|---|---|---|
| Net income 2022 | -54.28B -39.46M | Net income 2023 | -5.98B -4.35M | EV / Sales 2022 | 11 x |
| Net Debt 2022 | 16.03B 11.66M | Net Debt 2023 | 87.72B 63.77M | EV / Sales 2023 | 12.8 x |
| P/E ratio 2022 |
-18.7
x | P/E ratio 2023 |
-197
x | Employees | 110 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 82.78% |
More Fundamentals
* Assessed data
More news
| 1 day | -3.03% | ||
| 1 week | +1.19% | ||
| Current month | -17.11% | ||
| 1 month | -28.78% | ||
| 3 months | +44.01% | ||
| 6 months | +86.88% | ||
| Current year | +48.03% |
1 week
15 540.00
18 000.00
1 month
15 540.0022 150.00
Current year
9 950.0025 000.00
1 year
8 260.0025 000.00
3 years
8 260.0025 000.00
5 years
2 434.1625 000.00
10 years
539.6025 000.00
| Managers | Title | Age | Since |
|---|---|---|---|
Sang-Woo Nam
CEO | Chief Executive Officer | 66 | - |
Yang-Gon Jin
CEO | Chief Executive Officer | 58 | 15-12-10 |
Ki-Hwan Kim
CTO | Chief Tech/Sci/R&D Officer | 54 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yang-Gon Jin
CEO | Chief Executive Officer | 58 | 15-12-10 |
Sang-Woo Nam
CEO | Chief Executive Officer | 66 | - |
Yoon-Gi Baek
BRD | Director/Board Member | 61 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 4 M€ | -4.41% | - | |
| 0.00% | 7 M€ | +1.95% | - | |
| 0.00% | 117 M€ | +1.11% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 16,950 | -3.03% | 1,318,555 |
| 24-04-25 | 17,480 | -0.68% | 750,794 |
| 24-04-24 | 17,600 | +0.28% | 613,594 |
| 24-04-23 | 17,550 | +1.39% | 765,431 |
| 24-04-22 | 17,310 | +3.34% | 1,484,144 |
End-of-day quote Korea S.E., April 25, 2024
More quotes
HLB Life Science Co., Ltd. is a Korea-based company mainly engaged in the sale of pharmaceuticals. Along with subsidiaries, the Company operates its business through four segments. The Pharmaceutical Distribution segment is involved in the sale of pharmaceuticals and raw materials through SHINWHAADVANCE.CO.LTD. The Energy Business segment is engaged in energy service company (ESCO) business. It is equipped with equipments, assets and technical personnel to engage in energy saving investment business. The Bio Development segment is engaged in the development of extracorporeal circulation type bio space, hepatocyte treatment agents and hemostatic agents. The main products include anticancer drugs such as Tegatrabetan and Seclidemstat. The Other Business segment is involved in the investment of small business start-ups and venture businesses, as well as manufacturing and sale of light emitting diode (LED) products.
Sector
Pharmaceuticals
Calendar
2024-05-13
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +48.03% | 1.32B | |
| +17.35% | 71.39B | |
| +2.39% | 25.1B | |
| +5.38% | 8.59B | |
| +6.69% | 8.19B | |
| -20.96% | 7.91B | |
| +0.49% | 4.54B | |
| +17.12% | 4.31B | |
| -3.38% | 3.93B | |
| -2.61% | 3.86B |
- Stock Market
- Equities
- A067630 Stock
